Influenza Vaccines: What Do We Want and How Can We Get It?

Felix Geeraedts, Anke Huckriede*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademic

7 Citations (Scopus)

Abstract

Influenza vaccines have been in use for more than 60 years and have proven to be efficacious in protecting from influenza infections during epidemics and the recent H1N1 pandemic. The development of influenza vaccines has so far been largely based on empirical grounds, which leaves room for vaccine improvement by implementation of recent insights in innate and adaptive immunity. Also, evaluation and approval of new vaccines rely on rather broad correlates of protection such as the hemagglutination inhibition titre, thereby neglecting qualitative aspects of the immune response. Here we discuss how current inactivated influenza vaccine formulations differ in the type of immune response they elcit, their protective capacity, and what causes these differences. Finally, we will discuss how this knowledge can guide the development of new adjuvants that optimize the protective efficacy of influenza vaccines.

Original languageEnglish
Title of host publicationCROSSROADS BETWEEN INNATE AND ADAPTIVE IMMUNITY III
EditorsB Pulendran, PD Katsikis, SP Schoenberger
Place of PublicationBERLIN
PublisherSpringer
Pages161-174
Number of pages14
ISBN (Print)978-1-4419-5631-6
DOIs
Publication statusPublished - 2011

Publication series

NameAdvances in Experimental Medicine and Biology
PublisherSPRINGER-VERLAG BERLIN
Volume780
ISSN (Print)0065-2598

Keywords

  • A/DUCK/SINGAPORE/97 H5N3 VACCINE
  • INACTIVATED WHOLE VIRUS
  • BLOOD MONONUCLEAR-CELLS
  • A H1N1 VIRUS
  • PANDEMIC INFLUENZA
  • MF59-ADJUVANTED INFLUENZA
  • ANTIBODY-RESPONSES
  • IMMUNE-RESPONSES
  • SUBUNIT VACCINES
  • RANDOMIZED-TRIAL

Cite this